107 related articles for article (PubMed ID: 15570084)
1. Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies.
Zimmerman TM; Harlin H; Odenike OM; Berk S; Sprague E; Karrison T; Stock W; Larson RA; Ratain MJ; Gajewski TF
J Clin Oncol; 2004 Dec; 22(23):4816-22. PubMed ID: 15570084
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.
Cloughesy TF; Kuhn J; Robins HI; Abrey L; Wen P; Fink K; Lieberman FS; Mehta M; Chang S; Yung A; DeAngelis L; Schiff D; Junck L; Groves M; Paquette S; Wright J; Lamborn K; Sebti SM; Prados M
J Clin Oncol; 2005 Sep; 23(27):6647-56. PubMed ID: 16170172
[TBL] [Abstract][Full Text] [Related]
3. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer.
Zujewski J; Horak ID; Bol CJ; Woestenborghs R; Bowden C; End DW; Piotrovsky VK; Chiao J; Belly RT; Todd A; Kopp WC; Kohler DR; Chow C; Noone M; Hakim FT; Larkin G; Gress RE; Nussenblatt RB; Kremer AB; Cowan KH
J Clin Oncol; 2000 Feb; 18(4):927-41. PubMed ID: 10673536
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas.
Widemann BC; Salzer WL; Arceci RJ; Blaney SM; Fox E; End D; Gillespie A; Whitcomb P; Palumbo JS; Pitney A; Jayaprakash N; Zannikos P; Balis FM
J Clin Oncol; 2006 Jan; 24(3):507-16. PubMed ID: 16421428
[TBL] [Abstract][Full Text] [Related]
5. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial.
Karp JE; Lancet JE; Kaufmann SH; End DW; Wright JJ; Bol K; Horak I; Tidwell ML; Liesveld J; Kottke TJ; Ange D; Buddharaju L; Gojo I; Highsmith WE; Belly RT; Hohl RJ; Rybak ME; Thibault A; Rosenblatt J
Blood; 2001 Jun; 97(11):3361-9. PubMed ID: 11369625
[TBL] [Abstract][Full Text] [Related]
6. A phase I, pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignancies.
Patnaik A; Eckhardt SG; Izbicka E; Tolcher AA; Hammond LA; Takimoto CH; Schwartz G; McCreery H; Goetz A; Mori M; Terada K; Gentner L; Rybak ME; Richards H; Zhang S; Rowinsky EK
Clin Cancer Res; 2003 Oct; 9(13):4761-71. PubMed ID: 14581347
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer.
Johnston SR; Hickish T; Ellis P; Houston S; Kelland L; Dowsett M; Salter J; Michiels B; Perez-Ruixo JJ; Palmer P; Howes A
J Clin Oncol; 2003 Jul; 21(13):2492-9. PubMed ID: 12829668
[TBL] [Abstract][Full Text] [Related]
8. Intermittent dosing of the farnesyl transferase inhibitor tipifarnib (R115777) in advanced malignant solid tumors: a phase I California Cancer Consortium Trial.
Lara PN; Law LY; Wright JJ; Frankel P; Twardowski P; Lenz HJ; Lau DH; Kawaguchi T; Gumerlock PH; Doroshow JH; Gandara DR
Anticancer Drugs; 2005 Mar; 16(3):317-21. PubMed ID: 15711184
[TBL] [Abstract][Full Text] [Related]
9. Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer.
Crul M; de Klerk GJ; Swart M; van't Veer LJ; de Jong D; Boerrigter L; Palmer PA; Bol CJ; Tan H; de Gast GC; Beijnen JH; Schellens JH
J Clin Oncol; 2002 Jun; 20(11):2726-35. PubMed ID: 12039935
[TBL] [Abstract][Full Text] [Related]
10. Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma.
Alsina M; Fonseca R; Wilson EF; Belle AN; Gerbino E; Price-Troska T; Overton RM; Ahmann G; Bruzek LM; Adjei AA; Kaufmann SH; Wright JJ; Sullivan D; Djulbegovic B; Cantor AB; Greipp PR; Dalton WS; Sebti SM
Blood; 2004 May; 103(9):3271-7. PubMed ID: 14726402
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer.
Kelly WK; O'Connor OA; Krug LM; Chiao JH; Heaney M; Curley T; MacGregore-Cortelli B; Tong W; Secrist JP; Schwartz L; Richardson S; Chu E; Olgac S; Marks PA; Scher H; Richon VM
J Clin Oncol; 2005 Jun; 23(17):3923-31. PubMed ID: 15897550
[TBL] [Abstract][Full Text] [Related]
12. Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure.
Cortes J; Quintás-Cardama A; Garcia-Manero G; O'Brien S; Jones D; Faderl S; Ebarb T; Giles F; Thomas D; Kantarjian H
Cancer; 2007 Nov; 110(9):2000-6. PubMed ID: 17849425
[TBL] [Abstract][Full Text] [Related]
13. Farnesyl protein transferase inhibitors as targeted therapies for hematologic malignancies.
Karp JE
Semin Hematol; 2001 Jul; 38(3 Suppl 7):16-23. PubMed ID: 11523024
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndrome.
Kurzrock R; Kantarjian HM; Blascovich MA; Bucher C; Verstovsek S; Wright JJ; Pilat SR; Cortes JE; Estey EH; Giles FJ; Beran M; Sebti SM
Clin Cancer Res; 2008 Jan; 14(2):509-14. PubMed ID: 18223226
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome.
Kurzrock R; Albitar M; Cortes JE; Estey EH; Faderl SH; Garcia-Manero G; Thomas DA; Giles FJ; Ryback ME; Thibault A; De Porre P; Kantarjian HM
J Clin Oncol; 2004 Apr; 22(7):1287-92. PubMed ID: 15051776
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies.
Kurtzberg J; Ernst TJ; Keating MJ; Gandhi V; Hodge JP; Kisor DF; Lager JJ; Stephens C; Levin J; Krenitsky T; Elion G; Mitchell BS
J Clin Oncol; 2005 May; 23(15):3396-403. PubMed ID: 15908652
[TBL] [Abstract][Full Text] [Related]
17. A phase I and pharmacological study of the farnesyl protein transferase inhibitor L-778,123 in patients with solid malignancies.
Britten CD; Rowinsky EK; Soignet S; Patnaik A; Yao SL; Deutsch P; Lee Y; Lobell RB; Mazina KE; McCreery H; Pezzuli S; Spriggs D
Clin Cancer Res; 2001 Dec; 7(12):3894-903. PubMed ID: 11751480
[TBL] [Abstract][Full Text] [Related]
18. Phase 1 trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifarnib in children and adolescents with refractory leukemias: a report from the Children's Oncology Group.
Widemann BC; Arceci RJ; Jayaprakash N; Fox E; Zannikos P; Goodspeed W; Goodwin A; Wright JJ; Blaney SM; Adamson PC; Balis FM
Pediatr Blood Cancer; 2011 Feb; 56(2):226-33. PubMed ID: 20860038
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies.
Badar T; Cortes JE; Ravandi F; O'Brien S; Verstovsek S; Garcia-Manero G; Kantarjian H; Borthakur G
Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):433-438.e2. PubMed ID: 25795639
[TBL] [Abstract][Full Text] [Related]
20. Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial.
Luger SM; Wang VX; Rowe JM; Litzow MR; Paietta E; Ketterling RP; Lazarus H; Rybka WB; Craig MD; Karp J; Cooper BW; Makary AZ; Kaminer LS; Appelbaum FR; Larson RA; Tallman MS
Leuk Res; 2021 Dec; 111():106736. PubMed ID: 34773794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
